retatrutide expected approval date approval: FDA status, clinical trial results, and when it could be available Retatrutide (LY-3437943) Market Analysis, 2033:
Description
Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
The pharmacotherapy it offers (semaglutide) has the strongest weight-loss evidence base of any currently available anti-obesity agent
Severe or worsening symptoms: Extensive redness, swelling, fissures, or ulcerations may indicate complicated infection requiring prescription antifungal therapy rather than over-the-counter treatments
doi: 10.1586/17474124.2016.1129898
BMJ, 389, r1344
That year one in eight people were thought to be living with obesity around the world (WHO 2024)
